CSRxP Statement on Mylan’s EpiPen Announcement

After weeks of intense scrutiny on its pricing practices, Mylan Pharmaceuticals announced today that it would offer a coupon to patients that cannot afford life-saving EpiPens. Mylan’s public relations move does nothing address the real affordability problem facing American families: the underlying price of the medication.

Read more

New CMS Report Shows Prescription Drug Price Hikes Are Adding Up for Taxpayers

“Prescription drug prices rise faster than inflation every year and taxpayers are footing the bill for these higher prices. Even if you don’t take a medication, you’re paying for it,” Rother noted.

Read more

Analysis Shows New Cholesterol Medications Are Not Cost Effective

“The dangerous trend of high-priced drugs has to be reversed and a common-sense solution like measuring the value and cost-effectiveness of medications is one necessary step to fix the broken prescription drug market, but it must also be combined with increased transparency and competition.”

Read more

Avalere’s Recent Drug Cost Study: Critically Flawed

It’s widely known that prescription drug prices are on the rise, but a new study attempts to undermine the
role skyrocketing prescription drug prices play in increasing health care costs. The truth is that the study is
critically flawed.

Read more